• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by EQRx Inc.

    2/14/22 12:36:05 PM ET
    $EQRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EQRX alert in real time by email
    SC 13G 1 d296782dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Schedule 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.     )*

     

     

    EQRx, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    26886C107

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on following pages)

     

     

     


    CUSIP No. 26886C107    13G        

     

      1    

      NAME OF REPORTING PERSONS

     

      GV 2019, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      47,252,687 (1)

       6  

      SHARED VOTING POWER

     

      See response to row 5.

       7  

      SOLE DISPOSITIVE POWER

     

      47,252,687 (2)

       8  

      SHARED DISPOSITIVE POWER

     

      See response to row 7.

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      47,252,687

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      9.69% (3)

    12  

      TYPE OF REPORTING PERSON

     

      PN

     

    (1)

    Consists of 47,252,687 shares of the Issuer’s Common Stock held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote the shares held directly by GV 2019, L.P.

    (2)

    Consists of 47,252,687 shares of the Issuer’s Common Stock held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to dispose of the shares held directly by GV 2019, L.P.

    (3)

    Based on 487,632,615 shares of the Issuer’s Common Stock outstanding as of December 17, 2021 as disclosed in the Issuer’s Form 8-K filed with the Securities and Exchange Commission on December 20, 2021.

     

    Page 2 of 11


    CUSIP No. 26886C107    13G        

     

      1    

      NAME OF REPORTING PERSONS

     

      GV 2019 GP, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      47,252,687 (1)

       6  

      SHARED VOTING POWER

     

      See response to row 5.

       7  

      SOLE DISPOSITIVE POWER

     

      47,252,687 (2)

       8  

      SHARED DISPOSITIVE POWER

     

      See response to row 7.

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      47,252,687

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      9.69% (3)

    12  

      TYPE OF REPORTING PERSON

     

      PN

     

    (1)

    Consists of 47,252,687 shares of the Issuer’s Common Stock held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote the shares held directly by GV 2019, L.P.

    (2)

    Consists of 47,252,687 shares of the Issuer’s Common Stock held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to dispose of the shares held directly by GV 2019, L.P.

    (3)

    Based on 487,632,615 shares of the Issuer’s Common Stock outstanding as of December 17, 2021 as disclosed in the Issuer’s Form 8-K filed with the Securities and Exchange Commission on December 20, 2021.

     

    Page 3 of 11


    CUSIP No. 26886C107    13G        

     

      1    

      NAME OF REPORTING PERSONS

     

      GV 2019 GP, L.L.C.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      47,252,687 (1)

       6  

      SHARED VOTING POWER

     

      See response to row 5.

       7  

      SOLE DISPOSITIVE POWER.

     

      47,252,687 (2)

       8  

      SHARED DISPOSITIVE POWER

     

      See response to row 7.

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      47,252,687

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      9.69% (3)

    12  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    Consists of 47,252,687 shares of the Issuer’s Common Stock held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote the shares held directly by GV 2019, L.P.

    (2)

    Consists of 47,252,687 shares of the Issuer’s Common Stock held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to dispose of the shares held directly by GV 2019, L.P.

    (3)

    Based on 487,632,615 shares of the Issuer’s Common Stock outstanding as of December 17, 2021 as disclosed in the Issuer’s Form 8-K filed with the Securities and Exchange Commission on December 20, 2021.

     

    Page 4 of 11


    CUSIP No. 26886C107    13G        

     

      1    

      NAME OF REPORTING PERSONS

     

      Alphabet Holdings LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      47,252,687 (1)

       6  

      SHARED VOTING POWER

     

      See response to row 5.

       7  

      SOLE DISPOSITIVE POWER.

     

      47,252,687 (2)

       8  

      SHARED DISPOSITIVE POWER

     

      See response to row 7.

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      47,252,687

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      9.69% (3)

    12  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    Consists of 47,252,687 shares of the Issuer’s Common Stock held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote the shares held directly by GV 2019, L.P.

    (2)

    Consists of 47,252,687 shares of the Issuer’s Common Stock held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to dispose of the shares held directly by GV 2019, L.P.

    (3)

    Based on 487,632,615 shares of the Issuer’s Common Stock outstanding as of December 17, 2021 as disclosed in the Issuer’s Form 8-K filed with the Securities and Exchange Commission on December 20, 2021.

     

    Page 5 of 11


    CUSIP No. 26886C107    13G        

     

      1    

      NAME OF REPORTING PERSONS

     

      XXVI Holdings Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      47,252,687 (1)

       6  

      SHARED VOTING POWER

     

      See response to row 5.

       7  

      SOLE DISPOSITIVE POWER.

     

      47,252,687 (2)

       8  

      SHARED DISPOSITIVE POWER

     

      See response to row 7.

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      47,252,687

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      9.69% (3)

    12  

      TYPE OF REPORTING PERSON

     

      CO

     

    (1)

    Consists of 47,252,687 shares of the Issuer’s Common Stock held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote the shares held directly by GV 2019, L.P.

    (2)

    Consists of 47,252,687 shares of the Issuer’s Common Stock held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to dispose of the shares held directly by GV 2019, L.P.

    (3)

    Based on 487,632,615 shares of the Issuer’s Common Stock outstanding as of December 17, 2021 as disclosed in the Issuer’s Form 8-K filed with the Securities and Exchange Commission on December 20, 2021.

     

    Page 6 of 11


    CUSIP No. 26886C107    13G        

     

      1    

      NAME OF REPORTING PERSONS

     

      Alphabet Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      47,252,687 (1)

       6  

      SHARED VOTING POWER

     

      See response to row 5.

       7  

      SOLE DISPOSITIVE POWER.

     

      47,252,687 (2)

       8  

      SHARED DISPOSITIVE POWER

     

      See response to row 7.

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      47,252,687

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      9.69% (3)

    12  

      TYPE OF REPORTING PERSON

     

      CO, HC

     

    (1)

    Consists of 47,252,687 shares of the Issuer’s Common Stock held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote the shares held directly by GV 2019, L.P.

    (2)

    Consists of 47,252,687 shares of the Issuer’s Common Stock held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to dispose of the shares held directly by GV 2019, L.P.

    (3)

    Based on 487,632,615 shares of the Issuer’s Common Stock outstanding as of December 17, 2021 as disclosed in the Issuer’s Form 8-K filed with the Securities and Exchange Commission on December 20, 2021.

     

    Page 7 of 11


    ITEM 1(A).    NAME OF ISSUER
       EQRx, Inc.
    ITEM 1(B).    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
      

    50 Hampshire Street

    Cambridge, MA 02139

    ITEM 2(A).    NAME OF PERSONS FILING:
      

    This statement is filed by the following entities, collectively referred to as the “Reporting Persons”:

     

    •  GV 2019, L.P., a Delaware limited partnership

     

    •  GV 2019 GP, L.P., a Delaware limited partnership

     

    •  GV 2019 GP, L.L.C., a Delaware limited liability company

     

    •  Alphabet Holdings LLC, a Delaware limited liability company

     

    •  XXVI Holdings Inc., a Delaware corporation, and

     

    •  Alphabet Inc., a Delaware corporation

     

    Each of GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may be deemed to have sole power to vote or sole power to dispose of the securities owned directly by GV 2019, L.P.

    ITEM 2(B).    ADDRESS OF PRINCIPAL BUSINESS OFFICE, OR, IF NONE, RESIDENCE:
       The address of the principal business office for each of the Reporting Persons is:
       1600 Amphitheatre Parkway
       Mountain View, CA 94043
    ITEM 2(C).    CITIZENSHIP:
       GV 2019, L.P. is a Delaware limited partnership, GV 2019 GP, L.P. is a Delaware limited partnership, GV 2019 GP, L.L.C. is a Delaware limited liability company, Alphabet Holdings LLC is a Delaware limited liability company, XXVI Holdings Inc. is a Delaware corporation, and Alphabet Inc. is a Delaware corporation.
    ITEM 2(D)/(E).    TITLE OF CLASS OF SECURITIES AND CUSIP NUMBER:
       Common Stock, par value $0.0001 per share
       CUSIP # 26886C107
    ITEM 3.    Not Applicable.
    ITEM 4.    OWNERSHIP:

     

    Page 8 of 11


       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      

    (a)   Amount beneficially owned:

      

    See Row 9 of cover page for each Reporting Person.

      

    (b)   Percent of Class:

      

    See Row 11 of cover page for each Reporting Person.

      

    (c)   Number of shares as to which such person has:

      

    (i) Sole power to vote or to direct the vote:

      

    See Row 5 of cover page for each Reporting Person.

      

    (ii) Shared power to vote or to direct the vote:

      

    See Row 6 of cover page for each Reporting Person.

      

    (iii)Sole power to dispose or to direct the disposition of:

      

    See Row 7 of cover page for each Reporting Person.

      

    (iv)Shared power to dispose or to direct the disposition of:

      

    See Row 8 of cover page for each Reporting Person.

    ITEM 5.    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       Not Applicable.
    ITEM 6.    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       Under certain circumstances set forth in the limited partnership agreement of GV 2019, L.P., the limited partnership agreement of GV 2019 GP, L.P., and the limited liability company agreement of GV 2019 GP, L.L.C., the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the issuer owned by each such entity of which they are a general partner, limited partner, or member.
    ITEM 7.    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       Not Applicable.
    ITEM 8.    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       Not Applicable.
    ITEM 9.    NOTICE OF DISSOLUTION OF GROUP:
       Not Applicable.
    ITEM 10.    CERTIFICATION:
       Not Applicable.

     

    Page 9 of 11


    SIGNATURES

    After reasonable inquiry and to the best of her or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: February 11, 2022

     

    GV 2019, L.P.
    By: GV 2019 GP, L.P., its General Partner
    By: GV 2019 GP, L.L.C., its General Partner
    By: Alphabet Holdings LLC, its Sole Member
    By:  

    /s/ Kathryn W. Hall

    Name:   Kathryn W. Hall
    Title:   Secretary
    GV 2019 GP, L.P.
    By: GV 2019 GP, L.L.C., its General Partner
    By: Alphabet Holdings LLC, its Sole Member
    By:  

    /s/ Kathryn W. Hall

    Name:   Kathryn W. Hall
    Title:   Secretary
    GV 2019 GP, L.L.C.
    By: Alphabet Holdings LLC, its Sole Member
    By:  

    /s/ Kathryn W. Hall

    Name:   Kathryn W. Hall
    Title:   Secretary
    Alphabet Holdings LLC
    By:  

    /s/ Kathryn W. Hall

    Name:   Kathryn W. Hall
    Title:   Secretary
    XXVI Holdings Inc.
    By:  

    /s/ Kathryn W. Hall

    Name:   Kathryn W. Hall
    Title:   Assistant Secretary
    Alphabet Inc.
    By:  

    /s/ Kathryn W. Hall

    Name:   Kathryn W. Hall
    Title:   Assistant Secretary

     

    Page 10 of 11


    EXHIBIT INDEX

     

    Exhibit

       Found on
    Sequentially
    Numbered Page
     

    Exhibit A: Agreement of Joint Filing

         12  

     

    Page 11 of 11

    Get the next $EQRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EQRX

    DatePrice TargetRatingAnalyst
    11/14/2022Neutral → Underweight
    JP Morgan
    11/11/2022$8.00 → $5.00Buy → Neutral
    Goldman
    11/11/2022$5.60 → $3.20Buy → Hold
    Jefferies
    8/16/2022$5.50Neutral
    JP Morgan
    6/13/2022$8.00Buy
    Goldman
    4/22/2022Outperform
    Cowen
    3/18/2022$5.60Buy
    Jefferies
    More analyst ratings

    $EQRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lifshitz Law PLLC Announces Investigations of EQRX, RVMD, NEWR, and RETA

      NEW YORK, Aug. 05, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRX to Revolution Medicines, Inc. Under the terms of the proposed merger, EQRX shareholders will receive the number of shares of Revolution Medicines, Inc. stock equal to the sum of ~7.69M Revolution Medicines, Inc. shares plus a number of shares equal to $870M divided by a price that is a 6% discount to the 5-day volume-weighted average Revolution Medicines Inc. share price measured in close proximity to the stockholder vote. If you are an EQRX investor, and would like additional information abo

      8/5/23 8:13:00 PM ET
      $EQRX
      $NEWR
      $RETA
      $RVMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

      Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independent Transaction Committee of EQRx Board to Consider Strategic Alternatives to Maximize Value for EQRx Stockholders Transaction Expected to Close in November 2023 REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ("Revolution Medicines" or the "Company") (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. ("EQRx") (NASDAQ:EQRX) today announced a definitive agr

      8/1/23 7:00:00 AM ET
      $EQRX
      $RVMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results

      Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated, high-value therapiesPrioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase 3 trial in first-line advanced endometrial cancer; enrollment in Phase 2 trial in first- and second-line advanced breast cancer near completion, providing a foundation for future combination development opportunitiesSeeking commercialization partnerships for aumolertinib (third-generation EGFR inhibitor)Terminating license agreements for sugemalimab (anti-PD-L1 antibody), nofazinlimab (anti-PD-1 antibody) and EQ121 (JAK-1 inhibitor)$1.3 billion in cash, cash equivalents and short-term inves

      5/8/23 4:01:57 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQRX
    Financials

    Live finance-specific insights

    See more
    • Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

      Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independent Transaction Committee of EQRx Board to Consider Strategic Alternatives to Maximize Value for EQRx Stockholders Transaction Expected to Close in November 2023 REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ("Revolution Medicines" or the "Company") (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. ("EQRx") (NASDAQ:EQRX) today announced a definitive agr

      8/1/23 7:00:00 AM ET
      $EQRX
      $RVMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results

      Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated, high-value therapiesPrioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase 3 trial in first-line advanced endometrial cancer; enrollment in Phase 2 trial in first- and second-line advanced breast cancer near completion, providing a foundation for future combination development opportunitiesSeeking commercialization partnerships for aumolertinib (third-generation EGFR inhibitor)Terminating license agreements for sugemalimab (anti-PD-L1 antibody), nofazinlimab (anti-PD-1 antibody) and EQ121 (JAK-1 inhibitor)$1.3 billion in cash, cash equivalents and short-term inves

      5/8/23 4:01:57 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023

      CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced it will host a conference call and webcast on Monday, May 8, 2023, at 4:30 p.m. ET to report its first quarter 2023 financial results and provide a business update. A live webcast of the call will be available on the "Investor Relations" page of the Company's website at https://investors.eqrx.com/news-events/events-presentations. To access the call by phone, participants should visit this link

      4/27/23 8:00:34 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EQRx downgraded by JP Morgan

      JP Morgan downgraded EQRx from Neutral to Underweight

      11/14/22 7:36:09 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EQRx downgraded by Goldman with a new price target

      Goldman downgraded EQRx from Buy to Neutral and set a new price target of $5.00 from $8.00 previously

      11/11/22 9:09:51 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EQRx downgraded by Jefferies with a new price target

      Jefferies downgraded EQRx from Buy to Hold and set a new price target of $3.20 from $5.60 previously

      11/11/22 7:14:21 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQRX
    SEC Filings

    See more
    • SEC Form 15-12G filed by EQRx Inc.

      15-12G - EQRx, Inc. (0001843762) (Filer)

      11/20/23 4:00:52 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by EQRx Inc.

      EFFECT - EQRx, Inc. (0001843762) (Filer)

      11/20/23 12:15:18 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by EQRx Inc.

      EFFECT - EQRx, Inc. (0001843762) (Filer)

      11/20/23 12:15:12 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nallicheri Melanie returned 10,157,393 shares to the company and exercised 626,999 shares at a strike of $2.21, closing all direct ownership in the company (SEC Form 4)

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:27:28 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Merksamer Samuel J.

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:18:02 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berns Paul L returned 627,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:18:04 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by EQRx Inc. (Amendment)

      SC 13G/A - EQRx, Inc. (0001843762) (Subject)

      11/17/23 4:23:37 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by EQRx Inc. (Amendment)

      SC 13D/A - EQRx, Inc. (0001843762) (Subject)

      11/17/23 6:00:34 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by EQRx Inc. (Amendment)

      SC 13D/A - EQRx, Inc. (0001843762) (Subject)

      11/15/23 5:27:53 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care